Suppression of S-Antigen-induced Experimental Autoimmune Uveoretinitis in Lewis Rats by Oral Administration with CGS-13080, A Thromboxane Synthetase Inhibitor

Qian Li, Juan S. Lopez, Rachel R. Caspi, Francois G. Roberge, Robert B. Nussenblatt, Peter F Kador, Chi Chao Chan

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Oral administration of CGS-13080 [imidazo (1, 5-α) pyridine-5-hexanoic acid], a thromboxane synthetase inhibitor, has been reported to cause a marked reduction in serum thromboxane B2 concentration in humans and animals. Since thromboxane metabolites play an important role in ocular inflammation, the effect of oral CGS-13080 in the development of experimental autoimmune uveoretinitis in Lewis rats has been investigated. Females were immunized with bovine S-antigen (S-Ag). Treatment was started on day 0 of immunization. Animals were divided into three groups. The control group was fed a standard pellet diet, while the treated groups were fed the standard diet supplemented with either a low dose (0·8 g per 10 kg pellet) or a high dose (1·6 g per 10 kg pellet) of CGS 13080. From day 10 after immunization, the eyes of these rats were examined daily for clinical evidence of experimental autoimmune uveoretinitis. On day 14, the eyes were collected for histologic study. The cellular immune responses were evaluated on the draining inguinal lymph nodes. Blood samples were also collected for the measurement of anti-S-Ag antibody production, thromboxane B2 and prostaglandin A2 levels. Clinical disease developed in 73·3% of the control rat group. 30·0% of the low-dose treated group and 17·6% of the high-dose group. The average histologic grade was 1·9 in the control group, 0·65 in low-dose group and 0·32 in high-dose group. Lymphocyte proliferation to S-Ag paralleled the clinical disease scores. Average stimulation indices were 10·9 in the controls, 7·5 in the low-dose group and 2·2 in the high-dose group. In treated groups, serum thromboxane B2 levels were significantly reduced with a concomitant increase in prostaglandin A2 levels, suggesting a shunting of cyclic endoperoxide metabolism. There was an increase of serum anti-S-Ag antibody level in all three groups, but no significant difference between control and treated groups. In conclusion, oral CGS-13080 mixed in the diet has an inhibitory effect on the development of experimental autoimmune uveoretinitis. The blockage of the efferent limb of immune response and inhibition of T lymphocytes in response to S-Ag may be involved in the mechanism.

Original languageEnglish (US)
Pages (from-to)601-608
Number of pages8
JournalExperimental Eye Research
Volume57
Issue number5
DOIs
StatePublished - Nov 1 1993

Fingerprint

Thromboxane-A Synthase
Oral Administration
Thromboxane B2
Antigens
Control Groups
Diet
Immunization
Serum
Thromboxane A2
Groin
Thromboxanes
Cellular Immunity
Antibody Formation
Extremities
Lymph Nodes
pirmagrel
Lymphocytes
Inflammation
T-Lymphocytes
Antibodies

Keywords

  • CGS-13080
  • S-antigen
  • experimental autoimmune uveoretinitis (EAU)
  • immune response
  • prostaglandins
  • thromboxane synthetase inhibitor

ASJC Scopus subject areas

  • Sensory Systems
  • Ophthalmology

Cite this

Suppression of S-Antigen-induced Experimental Autoimmune Uveoretinitis in Lewis Rats by Oral Administration with CGS-13080, A Thromboxane Synthetase Inhibitor. / Li, Qian; Lopez, Juan S.; Caspi, Rachel R.; Roberge, Francois G.; Nussenblatt, Robert B.; Kador, Peter F; Chan, Chi Chao.

In: Experimental Eye Research, Vol. 57, No. 5, 01.11.1993, p. 601-608.

Research output: Contribution to journalArticle

Li, Qian ; Lopez, Juan S. ; Caspi, Rachel R. ; Roberge, Francois G. ; Nussenblatt, Robert B. ; Kador, Peter F ; Chan, Chi Chao. / Suppression of S-Antigen-induced Experimental Autoimmune Uveoretinitis in Lewis Rats by Oral Administration with CGS-13080, A Thromboxane Synthetase Inhibitor. In: Experimental Eye Research. 1993 ; Vol. 57, No. 5. pp. 601-608.
@article{79ab5057deeb4ec8971e679835dc12c4,
title = "Suppression of S-Antigen-induced Experimental Autoimmune Uveoretinitis in Lewis Rats by Oral Administration with CGS-13080, A Thromboxane Synthetase Inhibitor",
abstract = "Oral administration of CGS-13080 [imidazo (1, 5-α) pyridine-5-hexanoic acid], a thromboxane synthetase inhibitor, has been reported to cause a marked reduction in serum thromboxane B2 concentration in humans and animals. Since thromboxane metabolites play an important role in ocular inflammation, the effect of oral CGS-13080 in the development of experimental autoimmune uveoretinitis in Lewis rats has been investigated. Females were immunized with bovine S-antigen (S-Ag). Treatment was started on day 0 of immunization. Animals were divided into three groups. The control group was fed a standard pellet diet, while the treated groups were fed the standard diet supplemented with either a low dose (0·8 g per 10 kg pellet) or a high dose (1·6 g per 10 kg pellet) of CGS 13080. From day 10 after immunization, the eyes of these rats were examined daily for clinical evidence of experimental autoimmune uveoretinitis. On day 14, the eyes were collected for histologic study. The cellular immune responses were evaluated on the draining inguinal lymph nodes. Blood samples were also collected for the measurement of anti-S-Ag antibody production, thromboxane B2 and prostaglandin A2 levels. Clinical disease developed in 73·3{\%} of the control rat group. 30·0{\%} of the low-dose treated group and 17·6{\%} of the high-dose group. The average histologic grade was 1·9 in the control group, 0·65 in low-dose group and 0·32 in high-dose group. Lymphocyte proliferation to S-Ag paralleled the clinical disease scores. Average stimulation indices were 10·9 in the controls, 7·5 in the low-dose group and 2·2 in the high-dose group. In treated groups, serum thromboxane B2 levels were significantly reduced with a concomitant increase in prostaglandin A2 levels, suggesting a shunting of cyclic endoperoxide metabolism. There was an increase of serum anti-S-Ag antibody level in all three groups, but no significant difference between control and treated groups. In conclusion, oral CGS-13080 mixed in the diet has an inhibitory effect on the development of experimental autoimmune uveoretinitis. The blockage of the efferent limb of immune response and inhibition of T lymphocytes in response to S-Ag may be involved in the mechanism.",
keywords = "CGS-13080, S-antigen, experimental autoimmune uveoretinitis (EAU), immune response, prostaglandins, thromboxane synthetase inhibitor",
author = "Qian Li and Lopez, {Juan S.} and Caspi, {Rachel R.} and Roberge, {Francois G.} and Nussenblatt, {Robert B.} and Kador, {Peter F} and Chan, {Chi Chao}",
year = "1993",
month = "11",
day = "1",
doi = "10.1006/exer.1993.1165",
language = "English (US)",
volume = "57",
pages = "601--608",
journal = "Experimental Eye Research",
issn = "0014-4835",
publisher = "Academic Press Inc.",
number = "5",

}

TY - JOUR

T1 - Suppression of S-Antigen-induced Experimental Autoimmune Uveoretinitis in Lewis Rats by Oral Administration with CGS-13080, A Thromboxane Synthetase Inhibitor

AU - Li, Qian

AU - Lopez, Juan S.

AU - Caspi, Rachel R.

AU - Roberge, Francois G.

AU - Nussenblatt, Robert B.

AU - Kador, Peter F

AU - Chan, Chi Chao

PY - 1993/11/1

Y1 - 1993/11/1

N2 - Oral administration of CGS-13080 [imidazo (1, 5-α) pyridine-5-hexanoic acid], a thromboxane synthetase inhibitor, has been reported to cause a marked reduction in serum thromboxane B2 concentration in humans and animals. Since thromboxane metabolites play an important role in ocular inflammation, the effect of oral CGS-13080 in the development of experimental autoimmune uveoretinitis in Lewis rats has been investigated. Females were immunized with bovine S-antigen (S-Ag). Treatment was started on day 0 of immunization. Animals were divided into three groups. The control group was fed a standard pellet diet, while the treated groups were fed the standard diet supplemented with either a low dose (0·8 g per 10 kg pellet) or a high dose (1·6 g per 10 kg pellet) of CGS 13080. From day 10 after immunization, the eyes of these rats were examined daily for clinical evidence of experimental autoimmune uveoretinitis. On day 14, the eyes were collected for histologic study. The cellular immune responses were evaluated on the draining inguinal lymph nodes. Blood samples were also collected for the measurement of anti-S-Ag antibody production, thromboxane B2 and prostaglandin A2 levels. Clinical disease developed in 73·3% of the control rat group. 30·0% of the low-dose treated group and 17·6% of the high-dose group. The average histologic grade was 1·9 in the control group, 0·65 in low-dose group and 0·32 in high-dose group. Lymphocyte proliferation to S-Ag paralleled the clinical disease scores. Average stimulation indices were 10·9 in the controls, 7·5 in the low-dose group and 2·2 in the high-dose group. In treated groups, serum thromboxane B2 levels were significantly reduced with a concomitant increase in prostaglandin A2 levels, suggesting a shunting of cyclic endoperoxide metabolism. There was an increase of serum anti-S-Ag antibody level in all three groups, but no significant difference between control and treated groups. In conclusion, oral CGS-13080 mixed in the diet has an inhibitory effect on the development of experimental autoimmune uveoretinitis. The blockage of the efferent limb of immune response and inhibition of T lymphocytes in response to S-Ag may be involved in the mechanism.

AB - Oral administration of CGS-13080 [imidazo (1, 5-α) pyridine-5-hexanoic acid], a thromboxane synthetase inhibitor, has been reported to cause a marked reduction in serum thromboxane B2 concentration in humans and animals. Since thromboxane metabolites play an important role in ocular inflammation, the effect of oral CGS-13080 in the development of experimental autoimmune uveoretinitis in Lewis rats has been investigated. Females were immunized with bovine S-antigen (S-Ag). Treatment was started on day 0 of immunization. Animals were divided into three groups. The control group was fed a standard pellet diet, while the treated groups were fed the standard diet supplemented with either a low dose (0·8 g per 10 kg pellet) or a high dose (1·6 g per 10 kg pellet) of CGS 13080. From day 10 after immunization, the eyes of these rats were examined daily for clinical evidence of experimental autoimmune uveoretinitis. On day 14, the eyes were collected for histologic study. The cellular immune responses were evaluated on the draining inguinal lymph nodes. Blood samples were also collected for the measurement of anti-S-Ag antibody production, thromboxane B2 and prostaglandin A2 levels. Clinical disease developed in 73·3% of the control rat group. 30·0% of the low-dose treated group and 17·6% of the high-dose group. The average histologic grade was 1·9 in the control group, 0·65 in low-dose group and 0·32 in high-dose group. Lymphocyte proliferation to S-Ag paralleled the clinical disease scores. Average stimulation indices were 10·9 in the controls, 7·5 in the low-dose group and 2·2 in the high-dose group. In treated groups, serum thromboxane B2 levels were significantly reduced with a concomitant increase in prostaglandin A2 levels, suggesting a shunting of cyclic endoperoxide metabolism. There was an increase of serum anti-S-Ag antibody level in all three groups, but no significant difference between control and treated groups. In conclusion, oral CGS-13080 mixed in the diet has an inhibitory effect on the development of experimental autoimmune uveoretinitis. The blockage of the efferent limb of immune response and inhibition of T lymphocytes in response to S-Ag may be involved in the mechanism.

KW - CGS-13080

KW - S-antigen

KW - experimental autoimmune uveoretinitis (EAU)

KW - immune response

KW - prostaglandins

KW - thromboxane synthetase inhibitor

UR - http://www.scopus.com/inward/record.url?scp=0027524226&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027524226&partnerID=8YFLogxK

U2 - 10.1006/exer.1993.1165

DO - 10.1006/exer.1993.1165

M3 - Article

C2 - 8282047

AN - SCOPUS:0027524226

VL - 57

SP - 601

EP - 608

JO - Experimental Eye Research

JF - Experimental Eye Research

SN - 0014-4835

IS - 5

ER -